Bolt Biotherapeutics, Inc. (BOLT)
US — Healthcare Sector
Automate Your Wheel Strategy on BOLT
With Tiblio's Option Bot, you can configure your own wheel strategy including BOLT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BOLT
- Rev/Share 0.0949
- Book/Share 1.2209
- PB 4.6358
- Debt/Equity 0.5279
- CurrentRatio 3.1344
- ROIC -0.9113
- MktCap 10850107.0
- FreeCF/Share -1.5113
- PFCF -0.1873
- PE -3.4256
- Debt/Assets 0.2878
- DivYield 0
- ROE -0.9675
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
BOLT
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events
Read More
About Bolt Biotherapeutics, Inc. (BOLT)
- IPO Date 2021-02-05
- Website https://www.boltbio.com
- Industry Biotechnology
- CEO Mr. William P. Quinn
- Employees 52
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.